PhoenixBio Co

PhoenixBio Co EBIT

The EBIT of PhoenixBio Co (6190.T) as of Nov 12, 2026 is 82.77 M JPY. In the previous year, EBIT was -135.17 M JPY — a change of -161.23% (higher).

EBIT

82.77 MJPY

YoY

-161.23%

Last updated:

In 2026, PhoenixBio Co's EBIT was 82.77 M JPY, a -161.23% increase from the -135.17 M JPY EBIT recorded in the previous year.

The PhoenixBio Co EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2020
-414.97 M JPY
Jan 1, 2021
-276.89 M JPY
Jan 1, 2022
-392.05 M JPY
Jan 1, 2023
509.41 M JPY
Jan 1, 2024
11.06 M JPY
Jan 1, 2025
-135.17 M JPY
Jan 1, 2026
82.77 M JPY
Jan 1, 2027 (e)
0.00 JPY
The PhoenixBio Co EBIT history
YEAREBITYoY
est0.00JPY-100.00%
82.77 MJPY-161.23%
-135.17 MJPY-1,321.80%
11.06 MJPY-97.83%
509.41 MJPY-229.93%
-392.05 MJPY+41.59%
-276.89 MJPY-33.27%
-414.97 MJPY+33.03%
-311.93 MJPY+16.13%
-268.62 MJPY-176.70%
350.22 MJPY+83.36%
191.00 MJPY+267.31%
52.00 MJPY-10.34%
58.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PhoenixBio Co Revenue

PhoenixBio Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
1.31 B JPY
-414.97 M JPY
-415.00 M JPY
Jan 1, 2021
1.01 B JPY
-276.89 M JPY
-238.00 M JPY
Jan 1, 2022
1.32 B JPY
-392.05 M JPY
-387.97 M JPY
Jan 1, 2023
2.12 B JPY
509.41 M JPY
493.33 M JPY
Jan 1, 2024
1.72 B JPY
11.06 M JPY
26.38 M JPY
Jan 1, 2025
1.54 B JPY
-135.17 M JPY
-445.65 M JPY
Jan 1, 2026
1.57 B JPY
82.77 M JPY
125.23 M JPY
Jan 1, 2027 (e)
0.00 JPY
0.00 JPY
0.00 JPY

PhoenixBio Co Margins

PhoenixBio Co stock margins

The PhoenixBio Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PhoenixBio Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PhoenixBio Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
66.03 %
-31.68 %
-31.68 %
Jan 1, 2021
58.03 %
-27.32 %
-23.48 %
Jan 1, 2022
54.94 %
-29.59 %
-29.28 %
Jan 1, 2023
73.28 %
23.98 %
23.23 %
Jan 1, 2024
69.67 %
0.64 %
1.54 %
Jan 1, 2025
71.89 %
-8.77 %
-28.91 %
Jan 1, 2026
75.95 %
5.29 %
8.00 %
Jan 1, 2027 (e)
75.95 %
0.00 %
0.00 %

PhoenixBio Co Stock analysis

What does PhoenixBio Co do? PhoenixBio Co., Ltd., identified by the ticker symbol 6190.T and ISIN JP3803010002, is a specialized entity operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. Headquartered in Higashihiroshima-shi, located in the Hiroshima-Ken prefecture of Japan, the company has established itself as a holding company focused on advanced biotechnological innovations. The firm went public on March 18, 2016, marking a significant milestone in its corporate development and allowing it to access broader capital markets to support its research and development initiatives. Despite its specialized and high-tech nature, PhoenixBio maintains a lean operational structure, currently employing 65 full-time staff members who are dedicated to driving the company's core technological objectives. The primary focus of PhoenixBio lies in the development of proprietary technologies for the mass propagation of human cells into laboratory animals. This niche area of research is critical for the pharmaceutical and biotech industries, as it addresses the limitations of traditional animal models in predicting human drug responses. By creating more physiologically relevant models, the company aims to improve the accuracy and efficiency of preclinical testing. A key component of this effort is the PXB Mouse segment, which is engaged in the sophisticated development of a specific type of mouse model. The PXB Mouse is engineered so that more than 70 percent of its liver tissue is replaced with human hepatocytes. This significant degree of humanization allows the mouse liver to perform metabolic functions much closer to those of a human liver, providing a more accurate platform for drug discovery. The PXB Mouse product is primarily utilized in the preclinical phase of drug discovery, a crucial stage where potential therapeutic compounds are evaluated for safety and efficacy before moving to human clinical trials. By using these humanized mice, pharmaceutical researchers can obtain more reliable data regarding drug metabolism, toxicity, and efficacy, potentially reducing the high failure rates often seen in later stages of clinical development. This technology represents a significant advancement in the field of life sciences tools, offering a bridge between in vitro studies and human clinical applications. As the company continues to refine its mass propagation techniques, it seeks to expand the applicability of its human cell propagation technologies, thereby contributing to the broader goal of improving drug development outcomes. The company’s website, https://phoenixbio.co.jp/, serves as the primary digital hub for stakeholders seeking further information on its ongoing projects and corporate updates. PhoenixBio Co is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing PhoenixBio Co's EBIT

PhoenixBio Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of PhoenixBio Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

PhoenixBio Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in PhoenixBio Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about PhoenixBio Co stock

EBIT of PhoenixBio Co is 82.77 M JPY in 2026.

EBIT of PhoenixBio Co changed from -135.17 M JPY to 82.77 M JPY, representing a -161.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT PhoenixBio Co since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's PhoenixBio Co historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — PhoenixBio Co

All Key Metrics — PhoenixBio Co